secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-11-05T11:04:15+00:00
Accession:  0001104659-26-122952
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cognition Therapeutics gets Nasdaq bid-price deficiency notice; Q3 net loss narrows to $4.1M
--------------------------------------------------------------------------------

- Nasdaq deficiency letter dated Nov. 3, 2026: CGTX closing bid below $1.00 for 30 consecutive business days; 180 days to May 3, 2027 to regain compliance.
- No immediate delisting; shares continue trading on Nasdaq Capital Market. Company may get a second 180-day period and could use a reverse stock split to cure.
- Q3 2026 net loss $4.1M, or $(0.04) per share, vs $4.9M, or $(0.06), in Q3 2025; R&D rose to $5.1M from $3.8M.
- Cash and restricted cash $31.5M at Sept. 30, 2026, plus $18.2M obligated NIA grant funds; runway estimated into Q4 2027.
- FDA aligned on Phase 3 endpoints for zervimesine (CT1812) in dementia with Lewy bodies; Phase 2 START topline expected in 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/0001104659-26-122952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/tm2629072d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-122952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer